Republished: Immune checkpoint inhibitor induced large vessel vasculitis
- 22 October 2020
- journal article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 59 (2) , 29-31
Abstract
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).Keywords
This publication has 8 references indexed in Scilit:
- Vasculitis associated with immune checkpoint inhibitors—a systematic reviewClinical Rheumatology, 2018
- Aftermath of induced inflammation: acute periaortitis due to nivolumab therapyBMJ Case Reports, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitisProceedings of the National Academy of Sciences, 2017
- Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the LiteratureArthritis Care & Research, 2016
- Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanomaJournal for ImmunoTherapy of Cancer, 2014
- Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4Arthritis & Rheumatology, 2014
- Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving IpilimumabJournal of Clinical Oncology, 2013